Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L. Hertz, Howard L. McLeod, Kouros Owzar et al.|Clinical Cancer Research|2016Cited by 57
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N. Patel, Howard L. McLeod, Chen Jiang et al.|Cancer|2014Cited by 35
Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical programOlivia M Dong, Deepak Voora, Jill Bates et al.|Pharmacogenomics|2021Cited by 33
BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelinesDanielle S. Chun, Julie A. Lynch, Vickie L. Venne et al.|Familial Cancer|2016Cited by 22
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyMichael J. Kelley, Daniel L. Hertz, Yusuke Nakamura et al.|Loyola eCommons (Loyola University of Chicago)|2020Cited by 4